An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6116-6124

  Song, Hong ^a   Shahverdi, Karineh ^a   Huso, David L ^a   Wang, Yuchuan ^a   Fox, James J ^a   Hobbs, Robert F ^a   Gimi, Barjor ^a   Gabrielson, Kathleen L ^a   Pomper, Martin G ^a   Tsui, Benjamin M ^a   Bhujwalla, Zaver ^a   Reilly, R Todd ^b   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY IN 111; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN;

ABDOMINAL DISTENSION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BIOLUMINESCENCE; BONE MARROW METASTASIS; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; HEART LEFT VENTRICLE; HISTOPATHOLOGY; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; ISOTOPE LABELING; LIVER METASTASIS; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PARALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN CANCER; SPLEEN METASTASIS; TRANSGENIC MOUSE; TUMOR REJECTION; ANIMAL; CANCER TRANSPLANTATION; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; METHODOLOGY; RAT; TIME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RATS; RECEPTOR, ERBB-2; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 58149163338     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4672     Document Type: Article

References (44)

1. American Cancer Society. Cancer facts and figures 2008; Atlanta (GA): American Cancer Society, Inc.; 2008. p. 17.
2. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis : markers and models. Nat Rev Cancer 2005;5:591-602.
3. Lee YT. NM Breast-carcinoma - pattern of metastasis at autopsy. J Surg Oncol 1983;23:175-80.
4. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the Neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992;89:10578-82.
5. Guy CT, Cardiff RD, Muller WJ. Induction of mammary-tumors by expression of polyomavirus middle T-oncogene - a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
6. Lin SCJ, Lee KF, Nikitin AY, et al. Somatic mutation of p53 leads to estrogen receptor α-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res 2004;64:3525-32.
7. Siegel PM, Shu WP, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003;100:8430-5.
8. Rosol TJ, Tannehill-Gregg SH, Leroy BE, Mandl S, Contag CH. Animal models of bone metastasis. Cancer 2003;97:748-57.
9. Kuperwasser C, Dessain S, Bierbaum BE, et al. A mouse mode of human breast cancer metastasis to human bone. Cancer Res 2005;65:6130-8.
10. Morikawa K, Walker SM, Jessup JM, Fidler IJ. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 1988;48:1943-8.
11. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59.
12. Kang YB, Siegel PM, Shu WP, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
13. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
14. Minn AJ, Kang YB, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005;115:44-55.
15. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5:796-806.
16. Andrechek ER, Muller WJ. Tyrosine kinase signalling in breast cancer - tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res 2000;2:211-6.
17. Chan R, Muller WJ, Siegel PM. Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors. Ann N Y Acad Sci 1999;889:45-51.
18. Reilly RT, Gottlieb MBC, Ercolini AM, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-76.
19. Machiels JPH, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61:3689-97.
20. Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201:1591-602.
21. Abbey CK, Borowsky AD, McGoldrick ET, et al. In vivo positron of progression-emission tomography imaging of progression and transformation inmodel of mammary neoplasia. Proc Natl Acad Sci US A 2004;101:11438-43.
22. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003;63:2723-7.
23. Ballangrud AM, Yang WH, Charlton DE, et al. Response of LNCaP spheroids after treatment with an α-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001;61:2008-14.
24. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone-marrow. Cancer Res 1988;48:6876-81.
25. Petrovsky A, Schellenberger E, Josephson L, et al. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 2003;63:1936-42.
26. Serganova I, Doubrovin M, Vider J, et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1signal transduction activity in tumors in living mice. Cancer Res 2004;64:6101-8.
27. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci US A 2001;98:9300-5.
28. Zhang GJ, Safran M, Wei WY, et al. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 2004;10:643-8.
29. Golman K, in't Zandt R, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized C-13 magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006;66:10855-60.
30. Acuff HB, Carter KJ, Fingleton B, et al. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res 2006;66:259-66.
31. van der Pluijm G, Que I, Sijmons B, et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005;65:7682-90.
32. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
33. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25(+) CD4(+) regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
34. Curiel TJ, Coukos G, Zou LH, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
35. Terabe M, Matsui S, Nob en-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
36. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-43.
37. Huang B, Pan PY, Li QS, et al. Gr-1(+)CD115(+) immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123-31.
38. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-27.
39. Re F, Srinivasan R, Igarashi T, Marincola F, Childs R. Green fluorescent protein expression in dendritic cells enhances their immunogenicity and elicits specific cytotoxic T-cell responses in humans. Exp Hematol 2004;32:210-7.
40. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003;63:6838-46.
41. Koehne G, Doubrovin M, Doubrovina E, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol 2003;21:405-13.
42. de Vries IJM, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-13.
43. Song H, Shahverdi K, Huso DL, et al. α-Particle emitter labeled monoclonal antibody [213Bi-7.16.4] (anti-HER-2/neu) targeting of breast cancer metastases in the neu NHER-2/neu transgenic mouse model. Cancer Res 2008;68:3873-80.
44. Nguyen DX, Massague J Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.